Low-Dose Allergen Sublingual Tablet for Content Uniformity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing sublingual tablets for allergen immunotherapy face challenges with poor content uniformity, stability, and production complexity, particularly for low-dose formulations, due to issues with powder flowability, tablet cracking, and high equipment costs.
Innovation Solution
A sublingual tablet formulation comprising protein raw material, lactose, mannitol, low-substituted hydroxypropyl cellulose, low-moisture microcrystalline cellulose, and magnesium stearate, combined with a direct powder compression process, which avoids granulation and drying, ensuring uniformity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If direct powder compression method is used to prepare low-dose sublingual tablets, then the process is simplified and heat-sensitive drugs are protected, but powder flowability is poor, tablet weight variation is large, and content uniformity is poor
Solution Approach 1:
The patent applies preliminary action by pre-mixing the protein raw material with excipients (lactose, mannitol, low-substituted hydroxypropyl cellulose, low-moisture microcrystalline cellulose, and magnesium stearate) in specific ratios before compression. This pre-mixing step ensures uniform distribution of the low-dose active ingredient throughout the tablet matrix, addressing the content uniformity issue while maintaining the simplicity of the direct compression process.
Solution Approach 2:
The patent employs parameter changes by optimizing the ratios of excipients to protein raw material. Specifically, it uses low-substituted hydroxypropyl cellulose (4-6%) and low-moisture microcrystalline cellulose (10-15%) as key components that improve powder flowability and compressibility. These parameter adjustments enable achieving both good content uniformity and process simplicity without requiring complex equipment.
2Manufacturing precision
If freeze-drying method is used to prepare allergen sublingual tablets, then content uniformity and stability are improved, but equipment cost and production complexity increase significantly
Solution Approach 1:
The patent extracts the freeze-drying step from the manufacturing process, replacing it with direct powder compression. By removing this complex equipment-intensive step while maintaining content uniformity through optimized excipient formulation, the patent achieves the same quality outcome with significantly reduced equipment complexity and production cost.
Solution Approach 2:
The patent uses conventional, readily available compression equipment instead of expensive specialized freeze-drying equipment. The formulation is designed to work with standard tablet compression machines, making the process accessible and cost-effective while still achieving the required content uniformity for low-dose allergen tablets.
3Strength
If wet granulation and compression method is used, then tablet hardness and integrity are improved, but heat-sensitive and moisture-sensitive drugs are degraded
Solution Approach 1:
The patent replaces the thermal and moisture-intensive wet granulation process with a mechanical direct compression process. By using low-moisture microcrystalline cellulose and optimized lubrication with magnesium stearate (0.4-0.6%), the patent achieves sufficient tablet hardness and integrity without exposing heat-sensitive and moisture-sensitive allergen proteins to degrading conditions.
4Strength
If high compressive force is applied during compression, then tablet hardness is improved, but crystal form transformation and reduced activity occur
Solution Approach 1:
The patent changes the compression parameters by using low-moisture microcrystalline cellulose (10-15%) which provides excellent compressibility and binding properties. This allows achieving adequate tablet hardness with moderate compressive force, preventing crystal form transformation and maintaining the biological activity of the allergen protein while ensuring sufficient mechanical strength for handling and dissolution.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves excellent content uniformity, stability, and ease of production, with tablets disintegrating rapidly under the tongue, ensuring effective systemic absorption of low-dose allergens without adverse effects.
Implementation Method 1
sublingual tablets are placed under the tongue and can be rapidly dissolved or disintegrated in saliva
Implementation Method 2
drugs are absorbed through the sublingual oral mucosa to exert systemic effects
Data Source
AI summary
A sublingual tablet and application thereof in desensitization therapy drug are provided. The sublingual tablet is a low-dose allergen sublingual tablet. The sublingual tablet includes freeze-dried powder of allergen protein, lactose, mannitol, low substituted hydroxypropyl cellulose, low moisture microcrystalline cellulose, and magnesium stearate. The freeze-drying process is adopted to obtain the freeze-dried powder of allergen protein, and the powder direct compression technology is adopted to obtain the sublingual tablet of allergen protein. The low-dose sublingual tablet has excellent properties, including appearance, hardness, tablet weight variation, disintegration time, taste, and uniformity of content, in particular has outstanding advantages in disintegration time, uniformity of content, stability, and preparation process, and has an industrial application prospect.